Inflammasome signaling is increasingly implicated across neurological disease. IL-18 has been investigated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and stroke, where changes in this biomarker have been associated with inflammatory activity and disease-related processes. When evaluated alongside NfL, GFAP, pTau, and other Simoa biomarkers, IL-18 can help connect inflammasome-associated immune signaling with downstream glial activation, neuronal injury, and disease pathology.
IL-18 is implicated in inflammatory and autoimmune conditions including psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Quantitative IL-18 measurement can support studies of inflammatory heterogeneity, pathway activity, patient stratification, and pharmacodynamic response.
IL-18 has context-dependent effects on anti-tumor immunity and is also being actively investigated as a component of emerging CAR-T and engineered cell therapy strategies. As IL-18-directed and IL-18-secreting therapeutic approaches advance into clinical research, reliable IL-18 measurement can support pharmacodynamic assessment, immune monitoring, and characterization of treatment-associated cytokine responses.
IL-18 provides a window into inflammasome-associated biology that is distinct from downstream measures of cellular injury or disease pathology. Reliable quantification across serum, plasma, and CSF creates an opportunity to follow this biology across disease stages, and therapeutic intervention, helping define not only if inflammation is present, but how it changes with disease and treatment.
EDTA Plasma, Serum, CSF
100×
2 µL/test for Serum/EDTA plasma; 17 µL/test for CSF
96
HD-X™
0.041 pg/mL
0.0064 pg/mL
0-7500 pg/mL for serum/EDTA plasma; 0-600 pg/mL for CSF
